{"commentary":{"count":137,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":59,"x_thread":43,"podcast":34,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04704934\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04704934","nct_id":"NCT04704934","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04704934. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants who will be randomized to receive a 6.4 mg/kg intravenous (IV) dose of trastuzumab deruxtecan once every 3 weeks on Day 1 of each 21-day cycle.","label":"Trastuzumab deruxtecan","type":"EXPERIMENTAL"},{"description":"Participants who will be randomized to receive a 8 mg/kg IV dose of ramucirumab on Days 1 and 15 in combination with 80 mg/m\\^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.","label":"Ramucirumab + paclitaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2026-08-31","type":"ESTIMATED"},"conditions":["Gastric Cancer, Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma"],"enrollment":{"count":490,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Trastuzumab deruxtecan","type":"DRUG"},{"name":"Ramucirumab","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"}],"last_update":"2026-05-27","lead_sponsor":"Daiichi Sankyo","official_title":"A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With Paclitaxel","timeFrame":"Time from date of randomization until death (due to any cause), up to approximately 36 months"}],"references":[{"citation":"Shitara K, Van Cutsem E, Gumus M, Lonardi S, de la Fouchardiere C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, Liu B, Fornaro L, Ryu MH, Lee J, Faustino C, Metges JP, Tabernero J, Franke F, Janjigian YY, Souza F, Jukofsky L, Zhao Y, Kamio T, Zaanan A, Pietrantonio F; DESTINY-Gastric04 Trial Investigators. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025 Jul 24;393(4):336-348. doi: 10.1056/NEJMoa2503119. Epub 2025 May 31.","pmid":"40454632","type":"DERIVED"},{"citation":"Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036.","pmid":"40341124","type":"DERIVED"}],"start_date":{"date":"2021-05-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","url":"https://clinicaltrials.gov/study/NCT04704934"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04704934"}